Nasopharyngeal Carcinoma Clinical Trials (April 2026): 142 Recruiting Interventional Studies

Last updated: April 18, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Stage

First-Line Locally Advanced (Curative Intent)

Standard treatment is GP induction + concurrent chemoRT. These trials test immunotherapy additions, radiation optimization, or EBV-guided de-escalation:

• Immunotherapy + standard treatment:
  • NCT06712888 - Toripalimab vs Placebo + GP induction (Phase 3)
  • NCT04453826 - Camrelizumab + chemoRT vs chemoRT alone (Phase 3)
  • NCT06749899 - QL1706 (PD-1/CTLA-4 bispecific) + chemoRT (Phase 3)
  • NCT07154069 - Adaptive immunotherapy for NPC (Phase 3)
  • NCT07524413 - Becotatug vedotin (MRG003) + PD-1 + chemoRT in high-risk LA-NPC (Phase 3)
  • NCT07459296 - Becotatug vedotin + sintilimab in locoregionally advanced NPC (Phase 3)
• Intensified for high-risk (detectable EBV DNA):
  • NCT05772208 - Camrelizumab + Nimotuzumab for EBV+ after 1 cycle GP (Phase 3)
  • NCT06437627 - TPC + Apatinib + Camrelizumab for high-risk (Phase 3)
  • NCT07496190 - Becotatug vedotin for LA-NPC with suboptimal response to induction (Phase 2)
• De-escalation for good responders (undetectable EBV DNA):
  • NCT05674305 - RT alone vs concurrent chemoRT (Phase 3)
  • NCT06092957 - Reduced-dose RT ± CCT for CR after induction (Phase 3)
  • NCT04448522 - Reduced vs conventional dose IMRT (Phase 3)
• Proton therapy:
  • NCT07340515 - Proton vs Photon IMRT (Phase 3)
  • NCT07000643 - Proton vs Photon therapy (Phase 3, non-inferiority)

Recurrent or Metastatic

Immunotherapy + chemotherapy is becoming standard. These trials test new combinations or targets:

• First-line R/M:
  • NCT05854849 - Gemcitabine + Camrelizumab + Apatinib vs GP + Cisplatin (Phase 3)
  • NCT06176301 - Tislelizumab + GX vs GP (Phase 3)
  • NCT06382780 - Tislelizumab + GP or TPC for bone metastasis (Phase 3)
• Second-line+ (after immunotherapy):
  • NCT06976190 - MRG003 (ADC) + Pucotenlimab vs chemo (Phase 3)
  • NCT06629597 - YL201 vs docetaxel/capecitabine (Phase 3)
  • NCT06259721 - Anti-PD1 + Nimotuzumab + Capecitabine (platinum-resistant)
  • NCT06676722 - SBRT + Nimotuzumab + Tislelizumab (oligoprogression after IO)
• Oligometastatic:
  • NCT04944914 - Camrelizumab + SBRT vs Camrelizumab alone (Phase 3)
  • NCT07235319 - Immediate vs salvage locoregional RT (Phase 3)

Locoregional Recurrence

For disease recurring in the nasopharynx/neck after prior treatment:

• Re-irradiation:
  • NCT05340491 - ChemoRT + Toripalimab vs ChemoRT alone (Phase 3)
  • NCT04453813 - Toripalimab + concurrent chemoRT (Phase 3)
  • NCT03907826 - PD-1 antibody + chemoRT for recurrent T3/T4 (Phase 3)
• Surgery + adjuvant:
  • NCT04778956 - Toripalimab + surgery vs surgery alone (Phase 3)
  • NCT05877872 - Reduced-target vs full-target resection (Phase 3)
  • NCT06912711 - Toripalimab + Nimotuzumab neoadjuvant/adjuvant

Novel Approaches

• EBV-targeted cellular therapy:
  • NCT05587543 - EBV CAR-T/TCR-T cells for NPC
• ADC (antibody-drug conjugate):
  • NCT06976190 - MRG003 (EGFR-ADC) + Pucotenlimab (Phase 3)
  • NCT06475300 - BL-B01D1 (EGFR×HER3 bispecific ADC) + PD-1
  • NCT06839066 - HLX43 (PD-L1 ADC) for R/M NPC (Phase 2)
• Bispecific antibody:
  • NCT06749899 - QL1706 (PD-1/CTLA-4) + chemoRT (Phase 3)

Showing selected notable trials. View all 142 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions